BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30160353)

  • 1. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma.
    Boucher AA; Mizuno T; Vinks AA; Goldstein SL; Tiao GM; Geller JI
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27425. PubMed ID: 30160353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis.
    Nijstad AL; van Eijkelenburg NKA; Kraal KCJM; Meijs MJM; de Kanter CTMM; Lilien MR; Huitema ADR
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):445-449. PubMed ID: 32816154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin pharmacokinetics in a child receiving peritoneal dialysis.
    Sebestyen J; Garg U; Lewing KB; Warady BA; Abdel-Rahman S; Blowey DL
    Pediatr Nephrol; 2010 Jun; 25(6):1185-9. PubMed ID: 20084400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.
    Thomas F; Veal GJ; El Balkhi S; Lafont T; Picard N; Brugières L; Chatelut E; Piguet C
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):361-365. PubMed ID: 29922990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue.
    Kobrinsky NL; Sjolander DE; Goldenberg JA; Ortmeier TC
    Pediatr Blood Cancer; 2005 Aug; 45(2):222-5. PubMed ID: 15770640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
    Perilongo G; Maibach R; Shafford E; Brugieres L; Brock P; Morland B; de Camargo B; Zsiros J; Roebuck D; Zimmermann A; Aronson D; Childs M; Widing E; Laithier V; Plaschkes J; Pritchard J; Scopinaro M; MacKinlay G; Czauderna P
    N Engl J Med; 2009 Oct; 361(17):1662-70. PubMed ID: 19846851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoblastoma and hypoplastic kidneys: a new association.
    Chan R; Mascarenhas L; Venkatramani R
    Pediatr Blood Cancer; 2014 Aug; 61(8):1476-8. PubMed ID: 24623570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature.
    Kamei K; Sako M; Ishikawa T; Sato M; Ogura M; Uno T; Kiyotani C; Mori T; Tanaka H; Ito S; Nakamura H
    Ther Apher Dial; 2015 Oct; 19(5):491-6. PubMed ID: 25916242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
    Häberle B; Bode U; von Schweinitz D
    Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.
    Schnater JM; Aronson DC; Plaschkes J; Perilongo G; Brown J; Otte JB; Brugieres L; Czauderna P; MacKinlay G; Vos A
    Cancer; 2002 Feb; 94(4):1111-20. PubMed ID: 11920482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor.
    Sasaki F; Matsunaga T; Iwafuchi M; Hayashi Y; Ohkawa H; Ohira M; Okamatsu T; Sugito T; Tsuchida Y; Toyosaka A; Nagahara N; Nishihira H; Hata Y; Uchino J; Misugi K; Ohnuma N;
    J Pediatr Surg; 2002 Jun; 37(6):851-6. PubMed ID: 12037748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent cisplatin treatment of children with high-risk hepatoblastoma.
    Zhang YT; Feng LH; Zhong XD; Wang LZ; Chang J
    J Pediatr Hematol Oncol; 2014 May; 36(4):271-5. PubMed ID: 24309602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
    von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
    Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
    Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
    J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant.
    Ortiz D; Harden A; Corrales-Medina FF; Saigal G; Tekin A; Garcia J
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29356335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
    Katzenstein HM; London WB; Douglass EC; Reynolds M; Plaschkes J; Finegold MJ; Bowman LC
    J Clin Oncol; 2002 Aug; 20(16):3438-44. PubMed ID: 12177104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.
    Malogolowkin MH; Katzenstein H; Krailo MD; Chen Z; Bowman L; Reynolds M; Finegold M; Greffe B; Rowland J; Newman K; Womer RB; London WB; Castleberry RP
    J Clin Oncol; 2006 Jun; 24(18):2879-84. PubMed ID: 16782927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of cisplatin and vindesine in a patient with chronic renal failure undergoing hemodialysis].
    Ayabe H; Uchikawa T; Kimino K; Tagawa Y; Kawahara K; Tomita M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3283-5. PubMed ID: 2782920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology.
    Pritchard J; Brown J; Shafford E; Perilongo G; Brock P; Dicks-Mireaux C; Keeling J; Phillips A; Vos A; Plaschkes J
    J Clin Oncol; 2000 Nov; 18(22):3819-28. PubMed ID: 11078495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.